GLP-1 has recently emerged at the forefront of drug development in NASH given the recent promising results of early-phase studies using both semaglutide [11] as well as liraglutide [53] and the fact that several GLP-1 receptor agonists are regulatory-agency-approved for the medical treatment of overweight and obesity as well as type two diabetes [54,55]. The gene discussed is GLP1R; the disease is obesity disorder.